H.C. Wainwright raised its price target for Alector from $5.00 to $8.00, maintaining a Buy rating due to progress in its neurodegenerative disease pipeline. Alector develops treatments for Alzheimer's and Parkinson's using its Brain Carrier platform to deliver drugs across the blood-brain barrier. The company secured a $100 million upfront payment from a licensing deal with Genentech, extending its financial runway to 2029. This deal could bring up to $1.17 billion in milestones plus royalties, supporting Alector's shift toward bispecific antibodies and nucleic acid therapies.
Alector's price target was recently raised to $8. For readers following the health sector, here is Pluang's market snapshot as of Oct 14, 2026 23:21 WIB: out of 150 US health stocks, 78 rose and 71 fell. Among notable movers, Eli Lilly And Co (LLY) gained 4.08% to USD 1,214.15 with a typical hold time of 94 days, contrasting with Teladoc Health Inc (TDOC) and ClearPoint Neuro Inc (CLPT), which both declined over 4%, priced at USD 5.73 and USD 9.39 respectively, with CLPT seeing 100% buy order activity but a much shorter hold time of 10 days.
Fastenal reported strong Q3 2026 earnings, beating analyst expectations with EPS of $0.35 and revenue of $2.46 billion. The company saw a 20% rise in net income to $401.6 million and a 15.5% increase in revenue driven by robust manufacturing demand, ...
Remittix announced the public launch of its RTX token on November 24, 2026, marking the end of its presale phase which raised over $32 million from 40,000 participants. The project is testing its PayFi platform, which enables crypto-to-fiat and fiat-...
The global microbiology testing market is projected to grow rapidly at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching a market size of $13.7 billion by 2034. This growth is driven by the rising prevalence of infe...
State Street reported its Q3 2026 earnings with adjusted EPS of $3.69, slightly above the $3.68 estimate, marking its fourth consecutive quarterly earnings beat. Revenue rose 13% year-over-year to about $4 billion but missed analyst expectations of $...
Prologis is set to report its Q3 2026 earnings with analysts expecting earnings per share around $0.78 and revenue between $2.18 billion and $2.22 billion. The company shows strong operational trends including robust leasing activity, rising rental i...
